The Medical Advisor

Introduction to AI in Wearable Technology 2026 Artificial intelligence (AI) is rapidly transforming wearable technology in 2026, turning devices into intelligent, personalized health and fitness companions. These AI-powered wearables deliver real-time health monitoring, predictive analytics, and adaptive coaching, helping users optimize wellness and daily performance. This article synthesizes insights from industry reports and expert analyses on AI and wearable technology trends for 2025, highlighting the most impactful innovations driving the wearable tech market. Key Innovations in AI-Powered Wearable Technology 1. AI-Powered Health Monitoring for Early Disease Detection AI algorithms embedded in wearable devices enable continuous monitoring of vital signs such as heart rate, blood oxygen, and heart rhythm irregularities like atrial fibrillation. Early detection through AI-driven analytics allows users to identify potential health risks proactively, ...

Introduction: When Health Tracking Becomes Health Stress Wearables like the Apple Watch, Fitbit, and Oura Ring were designed to improve health awareness. A 2024 study examined the effects of smartwatch self-monitoring among police officers, a group that works under high stress and irregular schedules. Researchers found that tracking health data helped them become more aware of their stress levels and better at managing health-related habits. Another 2024 study published in PLOS Digital Health examined sleep data from wearable devices among first-year college students and compared it with self-reported stress levels. Researchers found that changes in sleep patterns, resting heart rate, and other physiological shifts appeared during periods of higher reported stress, showing how wearable data can reflect changes in stress levels over time. The Scripps DETECT Study  (Nature 2020) found that changes in resting pulse, sleep, and activity levels helped identify signs of illness be...

Abstract Background: Drug repurposing is gaining attention in oncology. Antiparasitic agents such as ivermectin, fenbendazole, and mebendazole have demonstrated preclinical anticancer activity. The potential synergy of these agents as a triple combination is of increasing interest. Objective: To review mechanistic rationale, preclinical evidence, and human observational data supporting the triple combination of ivermectin, fenbendazole, and mebendazole in cancer and discuss research gaps and limitations. Methods: Mechanistic studies, preclinical research, and publicly reported case testimonials were reviewed. Human evidence was synthesized using a PRISMA-style framework. Results: Preclinical studies demonstrate complementary mechanisms of action across all three agents. Five publicly reported cases suggest temporal associations with tumor shrinkage or biomarker improvements, though all are uncontrolled and confounded by prior or concurrent therapies. Conclusion: While biologically ...